BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SL-28 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SL-28\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07341737-2732@assetmemo.bio
DTSTAMP:20261121T004550Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:SL-28: Phase 1/2 readout est. (NCT07341737)
DESCRIPTION:SL-28\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: SL-28 f
 or Advanced Solid Tumours\nEstimated primary completion: 1 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sl-28#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07341737
URL:https://assetmemo.bio/drug/sl-28#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
